Startup Funding Cools In The Week To October 23 As Deal Sizes Shrink

Indian startups raised about 245.9 million US dollars across roughly 22 rounds in the week ended Thursday, October 23, according to trackers that compile weekly deal data. The tally was down by more than a quarter from the same week a year earlier, underscoring that capital remains available but is being deployed more selectively than at the peak of the funding cycle.

The week's larger cheques were concentrated in healthtech and artificial intelligence. A healthcare venture closed a Series B round of around 50 million dollars led by a US growth investor, while a consumer-focused company raised a sizeable seed round and an enterprise AI firm secured Series A money. The spread of deals suggests investors are still writing early-stage cheques even as late-stage activity stays subdued.

Where the money is going

For a second consecutive week, AI drew the largest share of capital, followed by healthtech. The pattern is consistent with a broader shift in which investors favour companies that can show a clear path to revenue and defensible technology, rather than funding growth-at-all-costs models. Semiconductor and deeptech names have also featured prominently in recent weeks, reflecting policy support for domestic chip design and manufacturing.

Founders and fund managers have described the current phase as a normalisation after the exuberance of earlier years. Valuations are being negotiated harder, diligence timelines have lengthened, and bridge rounds remain common as companies extend their runway rather than raise large primary rounds in a cautious market.

What it means

A single week's figures say little on their own, but the year-on-year decline fits a steadier theme through October: fewer mega-rounds, more mid-sized deals, and a premium on capital efficiency. For the wider economy, the composition matters as much as the headline number. Money flowing into AI, health and hardware points to bets on productivity and import substitution rather than discretionary consumer plays.

• Weekly totals remain volatile and can swing sharply on one or two large rounds.

• Early-stage activity is holding up better than late-stage, where exits and public-market conditions weigh on sentiment.

• Sectoral concentration in AI and healthtech has persisted for several weeks.

The real test will come in the closing weeks of the calendar year, when investors typically firm up allocations and several growth-stage companies are expected to test the market. For now, the signal is one of discipline rather than distress, with capital still moving but on tighter terms.